PMID- 11394884
OWN - NLM
STAT- MEDLINE
DCOM- 20010712
LR  - 20181130
IS  - 0006-291X (Print)
IS  - 0006-291X (Linking)
VI  - 284
IP  - 2
DP  - 2001 Jun 8
TI  - Amino-terminal fragment of urokinase-type plasminogen activator inhibits HIV-1 
      replication.
PG  - 346-51
AB  - CD8+ T lymphocytes have been shown to produce unidentified soluble factors active 
      in suppressing HIV-1 replication. In this study, we purified an HIV-1 suppressing 
      activity from the culture supernatant of an immortalized CD8+ T cell clone, 
      derived from an HIV-1 infected long-term nonprogressor, and identified this 
      activity as the amino-terminal fragment (ATF) of urokinase-type plasminogen 
      activator (uPA). ATF is catalytically inactive, but suppresses the release of 
      viral particles from the HIV-1 infected cell lines via binding to its receptor 
      CD87. In contrast, cell proliferation and the secretion of an HIV-1 LTR driven 
      reporter gene product were not affected by ATF. These findings suggest that ATF 
      may inhibit the assembly and budding of HIV-1, which provides a novel therapeutic 
      strategy for AIDS.
CI  - Copyright 2001 Academic Press.
FAU - Wada, M
AU  - Wada M
AD  - Laboratories for Bioengineering and Research, JCR Pharmaceuticals Company, Ltd., 
      2-2-10 Murotani, Nishi-ku, Kobe, 651-2241, Japan. wada-m@jcrpharm.co.jp
FAU - Wada, N A
AU  - Wada NA
FAU - Shirono, H
AU  - Shirono H
FAU - Taniguchi, K
AU  - Taniguchi K
FAU - Tsuchie, H
AU  - Tsuchie H
FAU - Koga, J
AU  - Koga J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (Culture Media, Conditioned)
RN  - 0 (Gene Products, gag)
RN  - 0 (HIV Antigens)
RN  - 0 (PLAUR protein, human)
RN  - 0 (Peptide Fragments)
RN  - 0 (Receptors, Cell Surface)
RN  - 0 (Receptors, Urokinase Plasminogen Activator)
RN  - 0 (Viral Proteins)
RN  - 0 (gag Gene Products, Human Immunodeficiency Virus)
RN  - 0 (p17 protein, Human Immunodeficiency Virus Type 1)
RN  - EC 3.4.21.73 (Urokinase-Type Plasminogen Activator)
SB  - IM
MH  - CD4-Positive T-Lymphocytes/cytology/drug effects/metabolism/virology
MH  - CD8-Positive T-Lymphocytes/cytology/*metabolism
MH  - Cell Division/drug effects
MH  - Cells, Cultured
MH  - Clone Cells
MH  - Coculture Techniques
MH  - Culture Media, Conditioned/chemistry/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Gene Products, gag/metabolism
MH  - Genes, Reporter/drug effects/genetics
MH  - HIV Antigens
MH  - HIV Infections/*drug therapy/metabolism
MH  - HIV Long Terminal Repeat/genetics
MH  - HIV-1/*drug effects/growth & development
MH  - Humans
MH  - Peptide Fragments/chemistry/*pharmacology
MH  - Receptors, Cell Surface/antagonists & inhibitors/metabolism
MH  - Receptors, Urokinase Plasminogen Activator
MH  - Sarcoma, Kaposi/metabolism
MH  - Survivors
MH  - Transfection
MH  - Urokinase-Type Plasminogen Activator/chemistry/*pharmacology
MH  - *Viral Proteins
MH  - Virus Replication/*drug effects
MH  - gag Gene Products, Human Immunodeficiency Virus
EDAT- 2001/06/08 10:00
MHDA- 2001/07/13 10:01
CRDT- 2001/06/08 10:00
PHST- 2001/06/08 10:00 [pubmed]
PHST- 2001/07/13 10:01 [medline]
PHST- 2001/06/08 10:00 [entrez]
AID - S0006-291X(01)94965-4 [pii]
AID - 10.1006/bbrc.2001.4965 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 2001 Jun 8;284(2):346-51. doi: 
      10.1006/bbrc.2001.4965.